Do alpha-reductase inhibitors prevent prostate cancer? 2008 practice guideline from the American society of clinical oncology and American urological association.
As new guidelines on the use of 5-alpha-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention produced by the American Society of Clinical Oncology (ASCO) and American Urological Association (AUA) have recently been published, the use of 5-ARIs is becoming of increasing interest. We analyzed the current evidence to support the use of 5-ARIs in the prevention of prostate cancer. We therefore compared the new guidelines of the ASCO and AUA with the current data concerning the use of 5-ARIs in the prevention of prostate cancer. At present, there is still an open debate going on whether or not it is advisable to incorporate the use of 5-ARIs as chemopreventive agents in daily practice.
Department of Urology, RWTH University of Aachen, Aachen, Germany.
David
D
Thüer
David
D
Pfister
Robin
R
Epplen
Bernhard
B
Brehmer
Axel
A
Heidenreich
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000494:pharmacology*; D058891:5-alpha Reductase Inhibitors; D018890:Chemoprevention; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D016896:Treatment Outcome
D058891:5-alpha Reductase Inhibitors; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase